-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125

Benzinga·07/02/2026 14:30:16
Listen to the news
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $115 to $125.